Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Universe Pharmaceuticals (UPC) Cash & Equivalents (2020 - 2025)

Universe Pharmaceuticals (UPC) has disclosed Cash & Equivalents for 6 consecutive years, with $70.2 million as the latest value for Q3 2025.

  • Quarterly Cash & Equivalents fell 99.76% to $70.2 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $70.2 million through Sep 2025, down 99.76% year-over-year, with the annual reading at $70.2 million for FY2025, 99.76% down from the prior year.
  • Cash & Equivalents hit $70.2 million in Q3 2025 for Universe Pharmaceuticals, down from $29.5 billion in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $29.5 billion in Q3 2024 to a low of $8.1 million in Q3 2021.
  • Historically, Cash & Equivalents has averaged $8.1 billion across 5 years, with a median of $5.3 billion in 2023.
  • Biggest five-year swings in Cash & Equivalents: surged 70604.67% in 2022 and later plummeted 99.76% in 2025.
  • Year by year, Cash & Equivalents stood at $8.1 million in 2021, then soared by 70604.67% to $5.7 billion in 2022, then decreased by 7.46% to $5.3 billion in 2023, then soared by 458.11% to $29.5 billion in 2024, then tumbled by 99.76% to $70.2 million in 2025.
  • Business Quant data shows Cash & Equivalents for UPC at $70.2 million in Q3 2025, $29.5 billion in Q3 2024, and $5.3 billion in Q3 2023.